Hofseth Biocare ASA: STRENGHTENS MEDICAL R&D AND IR FUNCTIONS

Hofseth BioCare ASA ("HBC") has entered into a consultancy agreement with Dr. Crawford Currie to strengthen the IR and communications functions of HBC.

Dr. Currie is based in London and is a qualified surgeon, having practiced within the NHS for several years before moving his focus onto pharmaceutical development and commercialization at AstraZeneca and then onto pharmaceutical stock analysis and research at HSBC and New Street Research, before moving onto fund management at Millennium Capital.

Dr Currie's experience across medical, pharmaceutical and financial services places him in an exceptional position to interpret and contextualise for investors HBC’s products and its ongoing research and development efforts.

The consultancy agreement has an initial term of 36 months. Dr. Currie has at the same time indirectly purchased 750,000 shares at NOK 6.00 in HBC through a 6.82 % shareholding in Brilliant Invest AS. For further information about Brilliant Invest AS and its HBC shareholdings, please see https://newsweb.oslobors.no/message/485842

For further information, please contact:
James Berger, Head of Investor Relations & Strategy of Hofseth BioCare ASA
Phone: +41 79 950 1034
E-mail: [email protected]

Jon Olav Ødegård, CFO of Hofseth BioCare ASA
Phone: +47 936 32 966
E-mail: [email protected]

About Hofseth BioCare ASA:
HBC is a Norwegian biotech company that develops high-value ingredients and finished products. Ingredients are further developed into discovery and pre-clinical studies in multiple clinics and university research labs in several countries. Lead clinical and pre-clinical candidates are development towards a Gastro-Intestinal (GI) Protective Medical Food, Medical Food to help treat age-related Sarcopenia, and future phase 1 studies on treatment of Anemia and NEC-IBS with Salmon Protein Hydrolysate fractions.

The company is founded on the core values of sustainability, traceability and optimal utilization of natural resources. Through an innovative hydrolysis technology, HBC can preserve the quality of lipids, proteins and calcium from fresh salmon off-cuts. Hofseth BioCare's headquarters are in Ålesund, Norway with branches in Oslo, Chicago, Mumbai, Palo Alto and Tokyo.

HBC is listed on Oslo Stock Exchange Axess list with ticker "HBC". More information about Hofseth BioCare at hofsethbiocare.com and facebook.com/hofsethbiocare

This information is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading Act

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• AAVantgarde Presents Encouraging Clinical Data from AAVB-081 and Preclinical Data Supporting AAVB-039 at EURetina 2026
• E&R Engineering to Launch New Malaysia Plant: Expanding Global Packaging Materials Production and Localized Services
• Seatrium and Karpowership Extend Collaboration with Ninth FSRU Conversion